EP3843746A4 - NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS - Google Patents

NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS Download PDF

Info

Publication number
EP3843746A4
EP3843746A4 EP19856239.9A EP19856239A EP3843746A4 EP 3843746 A4 EP3843746 A4 EP 3843746A4 EP 19856239 A EP19856239 A EP 19856239A EP 3843746 A4 EP3843746 A4 EP 3843746A4
Authority
EP
European Patent Office
Prior art keywords
taurolidine
neuroblastoma
treatment
hydrolysis products
hydrolysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19856239.9A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3843746A1 (en
Inventor
Bruce Reidenberg
Robert Diluccio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cormedix Inc
Original Assignee
Cormedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cormedix Inc filed Critical Cormedix Inc
Publication of EP3843746A1 publication Critical patent/EP3843746A1/en
Publication of EP3843746A4 publication Critical patent/EP3843746A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19856239.9A 2018-08-28 2019-08-28 NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS Pending EP3843746A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862723618P 2018-08-28 2018-08-28
PCT/US2019/048592 WO2020047113A1 (en) 2018-08-28 2019-08-28 Neuroblastoma treatment with taurolidine hydrolysis products

Publications (2)

Publication Number Publication Date
EP3843746A1 EP3843746A1 (en) 2021-07-07
EP3843746A4 true EP3843746A4 (en) 2022-10-19

Family

ID=69645349

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19856239.9A Pending EP3843746A4 (en) 2018-08-28 2019-08-28 NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS

Country Status (7)

Country Link
EP (1) EP3843746A4 (https=)
JP (2) JP2021535163A (https=)
KR (1) KR20210050544A (https=)
CN (1) CN113347976A (https=)
AU (1) AU2019330954B2 (https=)
CA (1) CA3111057A1 (https=)
WO (1) WO2020047113A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3843747A4 (en) * 2018-08-31 2022-12-28 CorMedix Inc. TAUROLIDINE TREATMENT FOR MYC-EXPRESSING TUMORS IN MAMMALIAN BODY
US20220313702A1 (en) * 2019-05-22 2022-10-06 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh
CN116769723B (zh) * 2023-08-09 2023-11-03 山东省成体细胞产业技术研究院有限公司 一种gd2嵌合抗原受体修饰的t细胞及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176360A1 (en) * 1999-12-06 2004-09-09 Paul Calabresi Use of taurolidine to treat tumors
US20050096314A1 (en) * 2001-04-03 2005-05-05 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
EP1248625A2 (en) * 1999-12-06 2002-10-16 Rhode Island Hospital Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
ATE354380T1 (de) * 2003-02-03 2007-03-15 Polaschegg Hans-Dietrich Dr Te Zusammensetzung zur prävention von infektionen durch subkutane prothesen
WO2005115357A2 (en) * 2004-05-14 2005-12-08 Hans-Dietrich Polaschegg Taurolidine formulations and delivery
EP1976531B1 (en) * 2006-01-06 2011-11-09 Ed. Geistlich Söhne AG für Chemische Industrie Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
CA2801309C (en) * 2010-06-01 2018-07-17 Geistlich Pharma Ag Methods and compositions for oral pharmaceutical therapy
MX2014011843A (es) * 2012-03-30 2014-12-10 Novartis Ag Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
JP7614714B2 (ja) * 2016-01-11 2025-01-16 コーメディクス・インコーポレーテッド 神経芽細胞腫及びその他のがん治療のための治療ナノ粒子

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176360A1 (en) * 1999-12-06 2004-09-09 Paul Calabresi Use of taurolidine to treat tumors
US20050096314A1 (en) * 2001-04-03 2005-05-05 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Cormedix Inc. announces agreement with nanoproteagen for its proprietary nanoparticle technology, Nanopro TM, in combination with CRMD-005 for pediatric neuroblastoma", INTERNET CITATION, 11 May 2016 (2016-05-11), XP002792142, Retrieved from the Internet <URL:http://www.cormedix.com/cormedix-inc-announces-agreement-with-nanoproteagen-for-its-proprietary-nanoparticle-technology-nanopro-in-combination-with-crmd-005-for-pediatric-neuroblastoma-2/> [retrieved on 20190617] *
BUCHHOLZ MARIE: "GMS | 130. Kongress der Deutschen Gesellschaft für Chirurgie | Effectivity and toxicity of Taurultam (TRLT) as anti-neoplastic agent in malignant tumor cells - in vitro study of pancreatic and colon cancer cell lines", 3 May 2013 (2013-05-03), pages 1 - 2, XP055959034, Retrieved from the Internet <URL:https://www.egms.de/static/de/meetings/dgch2013/13dgch861.shtml> [retrieved on 20220908] *
ESCHENBURG GEORG ET AL: "Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells", GENES & CANCER, vol. 5, no. 11-12, 9 October 2014 (2014-10-09), pages 460 - 469, XP055885452, DOI: 10.18632/genesandcancer.36 *
GONG LI ET AL: "The Pharmacokinetics of Taurolidine Metabolites in Healthy Volunteers", THE JOURNAL OF CLINICAL PHARMACOLOGY, vol. 47, no. 6, 1 June 2007 (2007-06-01), US, pages 697 - 703, XP055958727, ISSN: 0091-2700, Retrieved from the Internet <URL:http://dx.doi.org/10.1177/0091270007299929> DOI: 10.1177/0091270007299929 *
LUCKERT CHRISTIAN ET AL: "Taurolidine Specifically Inhibits Growth of Neuroblastoma Cell Lines In Vitro", JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY, vol. 36, no. 4, 1 May 2014 (2014-05-01), US, pages e219 - e223, XP055958541, ISSN: 1077-4114, Retrieved from the Internet <URL:http://dx.doi.org/10.1097/MPH.0000000000000149> DOI: 10.1097/MPH.0000000000000149 *
See also references of WO2020047113A1 *
STENDEL RUEDIGER ET AL: "Pharmacokinetics of Taurolidine following Repeated Intravenous Infusions Measured by HPLC-ESI-MS/MS of the Derivatives Taurultame and Taurinamide in Glioblastoma Patients :", CLINICAL PHARMACOKINETICS., vol. 46, no. 6, 1 January 2007 (2007-01-01), NZ, pages 513 - 524, XP055945305, ISSN: 0312-5963, Retrieved from the Internet <URL:http://dx.doi.org/10.2165/00003088-200746060-00005> DOI: 10.2165/00003088-200746060-00005 *

Also Published As

Publication number Publication date
KR20210050544A (ko) 2021-05-07
WO2020047113A1 (en) 2020-03-05
JP2021535163A (ja) 2021-12-16
CN113347976A (zh) 2021-09-03
AU2019330954A1 (en) 2021-04-22
EP3843746A1 (en) 2021-07-07
JP2024170590A (ja) 2024-12-10
AU2019330954B2 (en) 2025-11-13
CA3111057A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
EP3902524A4 (en) TREATMENT OF SKIN DISEASES WITH COMPOSITIONS CONTAINING AN EGFR INHIBITOR
EP3344274A4 (en) METHOD AND COMPOSITIONS FOR TREATING DISEASES RELATED TO ABNORMAL INFLAMMATORY REACTIONS
EP3436052A4 (en) TREATMENT OF MUSCLE WEAKNESS WITH ALKALINE PHOSPHATASES
EP3830139A4 (en) HIGHLY PURIFIED FUCANE FOR THE TREATMENT OF FIBROUS ADHESIONS
MA52219A (fr) Traitement de l&#39;hidradénite suppurée à l&#39;aide d&#39;inhibiteurs de jak
EP3558313A4 (en) SUBSTANCES FOR TREATING CONDITIONS RELATING TO FATTY LIVER
MA49664A (fr) Combinaisons d&#39;un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l&#39;endothéline
MA46954A (fr) Méthodes de traitement d&#39;états inflammatoires
EP3419633A4 (en) TREATMENT OF ALLERGIC EYE DISEASES WITH CYCLODEXTRINS
MA52861A (fr) Méthodes et compositions pour le traitement de l&#39;apnée du sommeil
MA46749A (fr) Méthodes de traitement du syndrome d&#39;alport à l&#39;aide d&#39;un méthyle de bardoxolone ou d&#39;analogues de ce dernier
EP3843746A4 (en) NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS
EP3684348A4 (en) TREATMENT OF DISEASES WITH ETERS FROM SELECTIVE RXR AGONISTS
EP3331527A4 (en) METHOD FOR TREATING DEVELOPMENT DISORDERS WITH PIPRADROL
EP3846830A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
MA44737A (fr) Compositions pour le traitement de troubles liés à l&#39;hyperkératose
EP3765057A4 (en) TREATMENT OF IMPLANTS WITH GENERALLY MODIFIED AMPHIPHILIC PEPTIDES
EP3634431A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT FOR HEPATITIS B
EP3728279A4 (en) GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS
EP3723768A4 (en) COMPOUNDS FOR TREATMENT AND PREVENTION OF EXTRACELLULAR HISTONE-MEDIATED PATHOLOGIES
FR3023938B1 (fr) Traitement des messages d&#39;alarmes et de maintenance d&#39;un aeronef
EP3920898A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF SLEEP APNEA
EP3490568A4 (en) TREATING SOLID TUMORS BY TARGETING DECTIN-1 SIGNALING
EP3927428A4 (en) METHODS OF TREATMENT OF RESPIRATORY DISEASES
MA51136A (fr) Traitement des maladies monogéniques à l&#39;aide d&#39;un anticorps anti-cd45rc

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20210326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220916

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20220912BHEP

Ipc: A61K 31/549 20060101ALI20220912BHEP

Ipc: A61K 31/541 20060101ALI20220912BHEP

Ipc: A61K 31/54 20060101AFI20220912BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240402